GSK3B and bone sarcoma: In bone sarcoma SW1353 and U2OS cells, the GSK-3β inhibitor SB-216763 substantially upregulated active β-catenin while total β-catenin had no detected change (Figure 4A), and enhanced reporter gene activity (Figure 4B).